DrugDev

Electronic trial applications and the next phase of site interactions

Monday, September 25, 2017

The Pulse on Technology by Elisa Cascade

The relationship between sponsors, CROs and clinical trial sites is a crucial aspect of clinical trial success. Historically, most trial communication has happened in person or via fax, but over the past 10 to 15 years, communication has largely shifted to email. Today, with the increasing popularity of electronic trial applications, sponsor, CRO and clinical trial site interactions are now beginning the next phase of process transformation with access to study resources, facilitated workflow and transparency for all parties.

[Read More]

Is eConsent adoption poised to grow?

Friday, September 1, 2017

Activity in the eConsent sector has risen considerably during the past six months, with Medidata’s acquisition of electronic informed consent pioneer Mytrus and the entry of new market players, even though widespread industry adoption of the technology has appeared to have stalled.

[Read More]

Site selection a continuing conundrum

Friday, September 1, 2017

For many companies, searching for clinical trial sites begins with a look at paper-based and spreadsheet tools that document where they had held earlier trials. Returning to familiar sites allows clinical trial teams to work with principal investigators with whom they have built relationships over time.

[Read More]

A critical need for timely site payments

Monday, August 28, 2017

The Pulse on Site Success by Christophe Berthoux

Research sites across the globe likely have felt the effects of delayed payments, inconsistent payment amounts and lack of explanation regarding what the payment was for. In a 2016 survey of Investigators conducted by DrugDev, getting paid “on time” was one of the top two burdens reported by sites. Receiving untimely payments not only produces financial stress to the site, it often leads to additional administrative load placed on staff members who must allocate resources to track down payments and deal with discrepancies.

[Read More]

Evidence-based site selection and study planning

Monday, August 14, 2017

The Pulse on Technology by Elisa Cascade

Any sponsor, CRO or third-party involved in site selection and study planning will tell you that data driven tools are the key to success. Thankfully, sponsors have a range of tools to choose from in today’s market that offer tables, charts, graphs, heatmaps, projections, scoring and in-depth reporting. The most important difference between these tools, however, is not the user interface, but rather the underlying data sources. So for sponsors, the question remains, “Are the tools responsible for successful study planning and site selection? Or should we worry about the data that feeds them instead?”

[Read More]

Vive le Mobile Revolution! But are clinical trial sites ready?

Wednesday, July 5, 2017

The Pulse on Technology by Elisa Cascade

In the past, the pharmaceutical industry has been reluctant to jettison old-fashioned methods in favor of new technologies. This has bolstered the industry’s critics, who argue that the old methods are to blame for the growing costs and timeframes of clinical development. However, this has begun to change over the past five years due to several factors, including regulatory authorities’ willingness to consider new approaches to clinical trial operations. As a result, technology is now being introduced into the industry at a rapid rate, with a high degree of trial use, but lower overall adoption1.

[Read More]

QuintilesIMS to buy DrugDev

Monday, June 26, 2017

QuintilesIMS has reportedly reached an agreement to buy DrugDev, a technology company that has built one of the industry’s largest global investigator networks and data sharing platforms, the latest in series of significant mergers among CROs during recent months.   

[Read More]

All for one and one for all: A call for a Three Musketeers approach to online profiles

Monday, May 22, 2017

The Pulse on Technology by Elisa Cascade

We all know there is an issue surrounding investigator participation in industry-sponsored clinical trials. Tufts University puts the figure for doctors declining to return for a second study at approximately 40%. At the same time, the number of global clinical trials continues to rise and increase in complexity. We’ve all read articles and attended conferences that expound the passionate view that investigators who commit their time and expertise need our help and encouragement. But if that’s the case, why do we as an industry fail to address the administrative burdens driving them away?

[Read More]

DrugDev, Informa partner to integrate investigator data with Spark

Friday, May 12, 2017

DrugDev and Citeline, part of Informa’s Pharma Intelligence vertical, announced that the two companies have integrated data from Citeline’s Trialtrove and Sitetrove intelligence platforms with the DrugDev Spark unified clinical operations suite. Indexing information captured by Citeline on more than 390,000 investigators across over 265,000 trials in more than 170 countries to the industry-standard DrugDev Golden Number adds significantly to the amount of information available for study planning and site identification through DrugDev Spark.

[Read More]